Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Puma Biotechnology nets $129.7mm through first public stock sale

Executive Summary

Oncology drug in-licenser Puma Biotechnology Inc. has netted $129.7mm through the company's first public stock sale since its October 2011 inception and reverse merger with a public shell. Puma sold 8.6mm shares (including the overallotment) at $16 each; it had originally filed in late September hoping to offer 6.5mm shares.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies